ASX:RMD

Stock Analysis Report

Executive Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases.

Snowflake

Fundamentals

Reasonable growth potential with acceptable track record.


Similar Companies

Share Price & News

How has ResMed's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RMD has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.5%

RMD

4.9%

AU Medical Equipment

0.9%

AU Market


1 Year Return

52.3%

RMD

46.9%

AU Medical Equipment

16.3%

AU Market

Return vs Industry: RMD exceeded the Australian Medical Equipment industry which returned 46.9% over the past year.

Return vs Market: RMD exceeded the Australian Market which returned 16.3% over the past year.


Shareholder returns

RMDIndustryMarket
7 Day3.5%4.9%0.9%
30 Day11.3%5.0%1.4%
90 Day8.1%13.4%6.0%
1 Year54.3%52.3%49.3%46.9%23.0%16.3%
3 Year180.9%168.3%69.5%62.0%41.6%22.3%
5 Year286.4%256.1%159.3%138.5%57.7%22.5%

Price Volatility Vs. Market

How volatile is ResMed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ResMed undervalued compared to its fair value and its price relative to the market?

50.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: RMD (A$21.44) is trading above our estimate of fair value (A$12.13)

Significantly Below Fair Value: RMD is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RMD is poor value based on its PE Ratio (50.3x) compared to the Medical Equipment industry average (32.9x).

PE vs Market: RMD is poor value based on its PE Ratio (50.3x) compared to the Australian market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: RMD is poor value based on its PEG Ratio (3.8x)


Price to Book Ratio

PB vs Industry: RMD is overvalued based on its PB Ratio (10x) compared to the AU Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is ResMed forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

13.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RMD's forecast earnings growth (13.3% per year) is above the savings rate (2.3%).

Earnings vs Market: RMD's earnings (13.3% per year) are forecast to grow faster than the Australian market (9.7% per year).

High Growth Earnings: RMD's earnings are forecast to grow, but not significantly.

Revenue vs Market: RMD's revenue (8% per year) is forecast to grow faster than the Australian market (3.7% per year).

High Growth Revenue: RMD's revenue (8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RMD's Return on Equity is forecast to be high in 3 years time (24.6%)


Next Steps

Past Performance

How has ResMed performed over the past 5 years?

2.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RMD has a high level of non-cash earnings.

Growing Profit Margin: RMD's current net profit margins (15.5%) are higher than last year (13.9%).


Past Earnings Growth Analysis

Earnings Trend: RMD's earnings have grown by 2.8% per year over the past 5 years.

Accelerating Growth: RMD's earnings growth over the past year (25%) exceeds its 5-year average (2.8% per year).

Earnings vs Industry: RMD earnings growth over the past year (25%) underperformed the Medical Equipment industry 29.5%.


Return on Equity

High ROE: RMD's Return on Equity (19.8%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is ResMed's financial position?


Financial Position Analysis

Short Term Liabilities: RMD's short term assets ($1.2B) exceeds its short term liabilities ($550.5M)

Long Term Liabilities: RMD's short term assets (1.2B) do not cover its long term liabilities (1.5B)


Debt to Equity History and Analysis

Debt Level: RMD's debt to equity ratio (57.6%) is considered high

Reducing Debt: RMD's debt to equity ratio has increased from 22.8% to 57.6% over the past 5 years.

Debt Coverage: RMD's debt is well covered by operating cash flow (47%).

Interest Coverage: RMD's interest payments on its debt are well covered by EBIT (15.9x coverage).


Balance Sheet

Inventory Level: RMD has a low level of unsold assets or inventory.

Debt Coverage by Assets: RMD's debt is not covered by short term assets (assets are 1x debt).


Next Steps

Dividend

What is ResMed's current dividend yield, its reliability and sustainability?

1.06%

Current Dividend Yield


Dividend Yield vs Market

company1.1%marketbottom25%2.4%markettop25%5.6%industryaverage1.5%forecastin3Years1.2%

Current dividend yield vs market & industry

Notable Dividend: RMD's dividend (1.06%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.37%).

High Dividend: RMD's dividend (1.06%) is low compared to the top 25% of dividend payers in the Australian market (5.56%).


Stability and Growth of Payments

Stable Dividend: RMD is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.

Growing Dividend: RMD is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: RMD is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RMD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of ResMed's salary, the management and board of directors tenure and is there insider trading?

6.7yrs

Average management tenure


CEO

Mick Farrell (47yo)

6.7yrs

Tenure

US$9,635,100

Compensation

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA has been the Chief Executive Officer of ResMed Inc. since March 1, 2013. Mr. Farrell served as President of Americas Operations at ResMed Inc. since  ...


CEO Compensation Analysis

Compensation vs Market: Mick's total compensation ($USD9.64M) is above average for companies of similar size in the Australian market ($USD3.65M).

Compensation vs Earnings: Mick's compensation has been consistent with company performance over the past year.


Management Age and Tenure

6.7yrs

Average Tenure

56yo

Average Age

Experienced Management: RMD's management team is seasoned and experienced (6.7 years average tenure).


Board Age and Tenure

6.0yrs

Average Tenure

61yo

Average Age

Experienced Board: RMD's board of directors are considered experienced (6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Peter Farrell (77yo)

    Founder & Non-Executive Chairman

    • Tenure: 5.8yrs
    • Compensation: US$791.18k
  • David Pendarvis (60yo)

    Chief Administrative Officer

    • Tenure: 8.5yrs
    • Compensation: US$2.72m
  • Connie Bienfait

    Director of Investor Relations

    • Tenure: 0yrs
  • Brett Sandercock (52yo)

    Chief Financial Officer

    • Tenure: 13.8yrs
    • Compensation: US$2.91m
  • Rob Douglas (59yo)

    President & COO

    • Tenure: 6.7yrs
    • Compensation: US$6.43m
  • Mick Farrell (47yo)

    CEO & Director

    • Tenure: 6.7yrs
    • Compensation: US$9.64m
  • Jim Hollingshead (56yo)

    President of Sleep Business

    • Tenure: 8.5yrs
    • Compensation: US$3.27m
  • Raj Sodhi (46yo)

    President of Software as a Service Business (SaaS)

    • Tenure: 2.3yrs
    • Compensation: US$2.93m
  • Bobby Ghoshal

    Chief Technology Officer

    • Tenure: 1.6yrs
  • Amy Wakeham

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs

Board Members

  • Rich Sulpizio (69yo)

    Independent Director

    • Tenure: 14.3yrs
    • Compensation: US$329.98k
  • Jack Wareham (78yo)

    Independent Director

    • Tenure: 14.8yrs
    • Compensation: US$315.01k
  • Peter Farrell (77yo)

    Founder & Non-Executive Chairman

    • Tenure: 5.8yrs
    • Compensation: US$791.18k
  • Ron Taylor (71yo)

    Lead Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$344.98k
  • Jan De Witte (55yo)

    Non-Executive Director

    • Tenure: 0.5yrs
    • Compensation: US$133.17k
  • Harjit Gill (54yo)

    Independent Director

    • Tenure: 1yrs
    • Compensation: US$288.17k
  • Mick Farrell (47yo)

    CEO & Director

    • Tenure: 6.7yrs
    • Compensation: US$9.64m
  • Carol Burt (61yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$332.98k
  • Karen Drexler (59yo)

    Independent Director

    • Tenure: 2yrs
    • Compensation: US$314.98k

Company Information

ResMed Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ResMed Inc.
  • Ticker: RMD
  • Exchange: ASX
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$21.151b
  • Listing Market Cap: US$31.054b
  • Shares outstanding: 143.79m
  • Website: https://www.resmed.com

Number of Employees


Location

  • ResMed Inc.
  • 9001 Spectrum Center Boulevard
  • San Diego
  • California
  • 92123
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RMDNYSE (New York Stock Exchange)YesCommon StockUSUSDJun 1995
RMEDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1995
0KW4LSE (London Stock Exchange)YesCommon StockGBUSDJun 1995
RMDWBAG (Wiener Boerse AG)YesCommon StockATEURJun 1995
RMD *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJun 1995
RMDASX (Australian Securities Exchange)CDI COM USD0.004 (10CDI/1SHS)AUAUDNov 1999
RSMD.FOTCPK (Pink Sheets LLC)CDI COM USD0.004 (10CDI/1SHS)USUSDNov 1999
RMEADB (Deutsche Boerse AG)CDI COM USD0.004 (10CDI/1SHS)DEEURNov 1999
RMDCHIA (Chi-X Australia)CDI COM USD0.004 (10CDI/1SHS)AUAUDNov 1999
RMDCHIA (Chi-X Australia)CDI COM USD0.004 (10CDI/1SHS)AUAUDNov 1999

Biography

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/17 10:31
End of Day Share Price2019/11/15 00:00
Earnings2019/09/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.